Scientists have identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia. The study points to a potentially new target for ...

Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around ...

Source: By IndependentOo, Dominik from Germany, Maximilian IV, Laitche, NASA; composite artwork by Belbury - CC BY 4.0, Wikimedia Working in his lab at the pharmaceutical company Sandoz in 1938, ...

A new study has demonstrated the role of two proteins in the activation and deactivation of the system through which drugs act against schizophrenia symptoms. An international study led by the ...

Reviva Pharmaceuticals Holdings Inc (NASDAQ:RVPH) announced the topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in adults with ...

(Reuters) -Reviva Pharmaceuticals' lead experimental drug to treat adults with schizophrenia helped reduce severity of disease symptoms in a late-stage study, sending the company's shares up nearly 8% ...

The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be used ...